Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment

In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe and Jennifer Fakish at Danaher Corporation. They discuss how antibody drug conjugates (ADCs) are transforming cancer care. With AI-powered pathology, doctors can now measure HER2 more precisely to match patients with the best treatments.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top